Brett Matthew Hall - Jul 29, 2021 Form 3 Insider Report for Immuneering Corp (IMRX)

Role
Chief Scientific Officer
Signature
/s/ Michael D. Bookman, Attorney-in-Fact for Brett M. Hall
Stock symbol
IMRX
Transactions as of
Jul 29, 2021
Transactions value $
$0
Form type
3
Date filed
7/29/2021, 08:51 PM
Next filing
Aug 4, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding IMRX Stock Option Jul 29, 2021 Class A Common Stock 91K $3.01 Direct F1
holding IMRX Stock Option Jul 29, 2021 Class A Common Stock 202K $3.01 Direct F2
holding IMRX Stock Option Jul 29, 2021 Class A Common Stock 175K $9.74 Direct F3
holding IMRX Series A Preferred Stock Jul 29, 2021 Class A Common Stock 1.64K Direct F4
holding IMRX Series B Preferred Stock Jul 29, 2021 Class A Common Stock 3.4K Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests and becomes exercisable as to 25% of the underlying shares on May 5, 2019 and then in equal monthly installments over the subsequent three years, subject to Dr. Hall's continued employment through each applicable vesting date.
F2 The option vests and becomes exercisable as to 25% of the underlying shares on November 1, 2020 and then in equal monthly installments over the subsequent three years, subject to Dr. Hall's continued employment through each applicable vesting date.
F3 The option vests and becomes exercisable as to 25% of the underlying shares on May 4, 2022 and then in equal monthly installments over the subsequent three years, subject to Dr. Hall's continued employment through each applicable vesting date.
F4 Each share of the Issuer's preferred stock is convertible on a one-for-one basis into shares of the Issuer's Class A common stock in certain circumstances and has no expiration date. The preferred stock will automatically convert into Class A common stock immediately prior to the closing of the Issuer's initial public offering.

Remarks:

Exhibit 24 - Power of Attorney